CL2016002517A1 - Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica. - Google Patents

Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.

Info

Publication number
CL2016002517A1
CL2016002517A1 CL2016002517A CL2016002517A CL2016002517A1 CL 2016002517 A1 CL2016002517 A1 CL 2016002517A1 CL 2016002517 A CL2016002517 A CL 2016002517A CL 2016002517 A CL2016002517 A CL 2016002517A CL 2016002517 A1 CL2016002517 A1 CL 2016002517A1
Authority
CL
Chile
Prior art keywords
alcoholic
treat
salt
manufacture
condition
Prior art date
Application number
CL2016002517A
Other languages
English (en)
Spanish (es)
Inventor
Charles A Mcwherter
Brian Roberts
Xueyan Wang
Yun-Jung Choi
David Karpf
Robert Martin
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53373532&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016002517(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of CL2016002517A1 publication Critical patent/CL2016002517A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
CL2016002517A 2014-04-11 2016-10-04 Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica. CL2016002517A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461978335P 2014-04-11 2014-04-11

Publications (1)

Publication Number Publication Date
CL2016002517A1 true CL2016002517A1 (es) 2017-05-05

Family

ID=53373532

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002517A CL2016002517A1 (es) 2014-04-11 2016-10-04 Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.

Country Status (27)

Country Link
US (7) US9381181B2 (index.php)
EP (1) EP3129018B1 (index.php)
JP (1) JP6865038B2 (index.php)
KR (1) KR102374499B1 (index.php)
CN (1) CN106163508A (index.php)
AU (1) AU2015243239B2 (index.php)
BR (1) BR112016023269A8 (index.php)
CA (1) CA2944139C (index.php)
CL (1) CL2016002517A1 (index.php)
CY (1) CY1122602T1 (index.php)
DK (1) DK3129018T3 (index.php)
EA (1) EA036704B1 (index.php)
ES (1) ES2764467T3 (index.php)
HR (1) HRP20192299T1 (index.php)
IL (1) IL248193B (index.php)
LT (1) LT3129018T (index.php)
MX (1) MX369921B (index.php)
NZ (1) NZ724740A (index.php)
PH (1) PH12016501978B1 (index.php)
PL (1) PL3129018T3 (index.php)
PT (1) PT3129018T (index.php)
RS (1) RS59637B1 (index.php)
SG (1) SG11201608077PA (index.php)
SI (1) SI3129018T1 (index.php)
SM (1) SMT202000019T1 (index.php)
UA (1) UA121208C2 (index.php)
WO (1) WO2015157697A1 (index.php)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2632967T3 (es) 2008-09-02 2017-09-18 Amarin Pharmaceuticals Ireland Limited Composición farmacéutica que comprende ácido eicosapentaenoico y ácido nicotínico y métodos de uso de la misma
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス，インコーポレイティド 小型高密度ｌｄｌ粒子を減少させる方法
EP4008327A1 (en) 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AU2010241571B2 (en) 2009-04-29 2014-06-26 Amarin Pharmaceuticals Ireland Limited Stable pharmaceutical composition and methods of using same
LT2443246T (lt) 2009-06-15 2018-03-26 Amarin Pharmaceuticals Ireland Limited Kompozicijos ir būdai, skirti trigliceridų sumažinimui, nepakeliant ldl-c lygio subjekte, kartu taikant statino terapiją
MX2012003555A (es) 2009-09-23 2012-07-03 Amarin Corp Plc Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma.
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
JP6307442B2 (ja) 2012-01-06 2018-04-04 アマリン ファーマシューティカルス アイルランド リミテッド 対象の高感度（ｈｓ−ｃｒｐ）のレベルを低下させる組成物および方法
EA039108B1 (ru) 2012-06-29 2021-12-06 Амарин Фармасьютикалз Айрлэнд Лимитед Способы уменьшения риска развития сердечно-сосудистого события у субъекта, получающего терапию статином
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US9814733B2 (en) * 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
DK3119384T3 (en) 2014-03-20 2018-12-03 Cymabay Therapeutics Inc TREATMENT OF INTRAHEPATHIC COLESTASTIC DISEASES
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
JP6865038B2 (ja) 2014-04-11 2021-04-28 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｎａｆｌｄおよびｎａｓｈの治療
SG11201609953XA (en) 2014-05-28 2016-12-29 Childrens Hosp Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
JP6804438B2 (ja) 2014-10-17 2020-12-23 チルドレンズ ホスピタル メディカル センター 多能性幹細胞を使用するヒト小腸のｉｎ ｖｉｖｏモデル、並びにそれを作製、及び使用する方法
WO2016154258A1 (en) * 2015-03-26 2016-09-29 T3D Therapeutics, Inc. Methods of treating liver disease using indane acetic acid derivatives
AU2016256552B2 (en) 2015-04-28 2021-04-01 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
WO2017049157A1 (en) * 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
WO2017139708A1 (en) 2016-02-10 2017-08-17 Synlogic, Inc. Bacteria engineered to treat nonalcoholic steatohepatitis (nash)
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
EP3452578B1 (en) 2016-05-05 2022-08-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
GB201614455D0 (en) 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
KR20240164965A (ko) * 2016-11-04 2024-11-21 칠드런즈 호스피탈 메디칼 센터 간 유사 장기 조성물 및 이를 제조 및 사용하는 방법
US10493363B2 (en) * 2016-11-09 2019-12-03 Activision Publishing, Inc. Reality-based video game elements
US11767515B2 (en) 2016-12-05 2023-09-26 Children's Hospital Medical Center Colonic organoids and methods of making and using same
JP7248586B2 (ja) 2017-04-14 2023-03-29 チルドレンズ ホスピタル メディカル センター 複数ドナー幹細胞組成物およびそれを作製する方法
EP4234536A3 (en) 2017-05-05 2023-10-25 Hepanova, Inc. Amino-aryl-benzamide compounds and methods of use thereof
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
EP3681537A1 (en) 2017-09-13 2020-07-22 Novartis AG Combinations comprising fxr agonists
JP2020536529A (ja) 2017-10-10 2020-12-17 チルドレンズ ホスピタル メディカル センター 食道組織および／または臓器組成物およびそれを作製する方法
US11260066B2 (en) 2017-10-27 2022-03-01 Samyang Corporation Inhibiting reduction of lean body mass and inhibiting accumulation of liver fat by administering allulose
MX2020005621A (es) 2017-12-06 2020-08-20 Basf As Derivados de acidos grasos para tratar la esteatohepatitis no alcoholica.
WO2019126626A1 (en) 2017-12-21 2019-06-27 Children's Hospital Medical Center Digitalized human organoids and methods of using same
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR102887406B1 (ko) 2018-07-26 2025-11-19 칠드런즈 호스피탈 메디칼 센터 간-담도-췌장 조직 및 이를 제조하는 방법
CA3112026A1 (en) 2018-09-12 2020-03-19 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
SI4056176T1 (sl) 2018-09-24 2024-09-30 Amarin Pharmaceuticals Ireland Limited Metode zmanjševanja tveganja za kardiovaskularne dogodke pri subjektu
SG11202104951RA (en) * 2018-11-16 2021-06-29 Cymabay Therapeutics Inc Combination treatment of nafld and nash
WO2020102351A1 (en) * 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
CN121081472A (zh) 2018-12-13 2025-12-09 拓臻股份有限公司 一种THRβ受体激动剂化合物及其制备方法和用途
CN114174494A (zh) 2019-05-31 2022-03-11 儿童医院医学中心 产生和扩增造血干细胞的方法
JP2022534398A (ja) 2019-05-31 2022-07-29 チルドレンズ ホスピタル メディカル センター 形成オルガノイド組成物およびその作製方法
WO2021041237A1 (en) 2019-08-23 2021-03-04 Terns, Inc. Thyroid hormone receptor beta agonist compounds
US12398127B2 (en) 2019-09-12 2025-08-26 Terns Pharmaceuticals, Inc. Thyroid hormone receptor beta agonist compounds
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
US20210145774A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
JP2023525571A (ja) * 2020-05-13 2023-06-16 ターンズ・ファーマシューティカルズ・インコーポレイテッド 肝障害の併用処置
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
WO2022238445A1 (en) * 2021-05-11 2022-11-17 Genfit Ppar-agonists for use in the treatment of liver failure

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
AU5359496A (en) 1995-03-06 1996-09-23 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
TR199801581T2 (xx) 1996-02-14 1998-10-21 Isis Pharmaceuticals, Inc. �ekerle de�i�tirilmi� bo�luklu oligon�kleotid'ler.
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
UA87467C2 (en) 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
CA2910191C (en) 2004-03-05 2022-03-08 The Trustees Of The Univeristy Of Pennsylvania The use of mtp inhibitors for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
WO2008091863A1 (en) 2007-01-23 2008-07-31 Kalypsys, Inc. Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス，インコーポレイティド 小型高密度ｌｄｌ粒子を減少させる方法
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
AU2014353246A1 (en) 2013-11-20 2016-06-16 Cymabay Therapeutics, Inc. Treatment of homozygous familial hypercholesterolemia
DK3119384T3 (en) 2014-03-20 2018-12-03 Cymabay Therapeutics Inc TREATMENT OF INTRAHEPATHIC COLESTASTIC DISEASES
JP6865038B2 (ja) * 2014-04-11 2021-04-28 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｎａｆｌｄおよびｎａｓｈの治療
AU2015279905A1 (en) 2014-06-26 2017-02-02 Cymabay Therapeutics, Inc. Treatment of severe hypertriglyceridemia

Also Published As

Publication number Publication date
SMT202000019T1 (it) 2020-03-13
BR112016023269A2 (pt) 2017-08-15
CA2944139A1 (en) 2015-10-15
EA036704B1 (ru) 2020-12-10
MX2016013375A (es) 2017-02-15
CY1122602T1 (el) 2021-03-12
US20180228752A1 (en) 2018-08-16
US9381181B2 (en) 2016-07-05
US10722483B2 (en) 2020-07-28
ES2764467T3 (es) 2020-06-03
US20190142776A1 (en) 2019-05-16
LT3129018T (lt) 2020-01-10
JP6865038B2 (ja) 2021-04-28
US20150290154A1 (en) 2015-10-15
PH12016501978B1 (en) 2023-07-12
SG11201608077PA (en) 2016-10-28
CA2944139C (en) 2020-11-03
DK3129018T3 (da) 2020-01-20
PL3129018T3 (pl) 2020-05-18
PT3129018T (pt) 2020-01-15
EP3129018B1 (en) 2019-10-23
US10342770B2 (en) 2019-07-09
MX369921B (es) 2019-11-26
US11179359B2 (en) 2021-11-23
AU2015243239B2 (en) 2019-11-14
EA201692050A1 (ru) 2017-01-30
US20180008566A1 (en) 2018-01-11
BR112016023269A8 (pt) 2021-06-29
WO2015157697A1 (en) 2015-10-15
IL248193B (en) 2019-03-31
JP2017513836A (ja) 2017-06-01
US20160324812A1 (en) 2016-11-10
CN106163508A (zh) 2016-11-23
AU2015243239A1 (en) 2016-10-20
HRP20192299T1 (hr) 2020-03-06
KR20160136451A (ko) 2016-11-29
US10188620B2 (en) 2019-01-29
SI3129018T1 (sl) 2020-02-28
RS59637B1 (sr) 2020-01-31
US9616039B2 (en) 2017-04-11
PH12016501978A1 (en) 2016-12-19
EP3129018A1 (en) 2017-02-15
UA121208C2 (uk) 2020-04-27
US20200009092A1 (en) 2020-01-09
US20210038546A1 (en) 2021-02-11
NZ724740A (en) 2019-11-29
KR102374499B1 (ko) 2022-03-14
US9962346B2 (en) 2018-05-08

Similar Documents

Publication Publication Date Title
CL2016002517A1 (es) Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.
CL2015003690A1 (es) Uso de pridopidina o una sal de la misma para preparar un medicamento útil en el tratamiento de la enfermedad de huntington.
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
EA201691582A1 (ru) Новые фармацевтические препараты
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
CL2016002971A1 (es) Combinación.
GT201400069A (es) Composiciones farmaceuticas
GB201411467D0 (en) 7-hydroxy cannabidiol (7-oh-cbd) for use in the treatment of non-alcoholic fatty liver disease (nafld)
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
BR112016020260A8 (pt) uso de um composto na fabricação de um medicamento para tratar uma doença colestática intra-hepática
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
PH12016502530A1 (en) Pharmaceutical compositions comprising dgla and use of same
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
MX377579B (es) Composición farmacéutica oral de isotretinoína con dosis baja y su proceso de preparación.
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
MX2017001461A (es) Terapia de combinacion.
MX390977B (es) Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontan que utilizan composiciones de udenafilo
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
CL2016001843A1 (es) Uso de una composición que comprende a) un compuesto de fórmula (ia) definida o una sal del mismo y b) un portador o excipiente farmacéuticamente aceptable para preparar un medicamento útil para tratar una afección alérgica en un mamífero.
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
ES2956684T8 (es) Productos para la administración de compuestos terapéuticos/de diagnóstico al corazón